Elionova AG

Traditional immunoassays in R&D and IVD are slow and complex. ElioDX™ revolutionizes this with real-time immunoassays delivering lab-grade results in 10 minutes via a simple, one-step disposable system. Initially targeting researchers in universities and biotech, we’ve trained labs and developed assays, expanding into IVD with evaluations underway. With a $3Bn R&D and $27Bn IVD market, we focus on early adopters for growth. Our scalable "printer and ink" model drives revenue via instruments and high-margin consumables. Offering unmatched speed, accuracy, and flexibility, ElioDX™ accelerates research, supports PoC diagnostics, and streamlines workflows, ensuring rapid adoption and market expansion.